Our team of procurement experts are working around the clock provide services to our healthcare clients by sourcing and delivering critical lifesaving pharmaceuticals at lightning fast speeds. We work closely with our supply partners and couriers to deliver prompt and cost effective solutions in emergency and market shortage situations. Contact Us
- FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density[9-10-2015] The U.S. Food and Drug Administration (FDA) has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures and added new information about decreased bone mineral density.
- FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines[12-16-2015] The U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics.
- What's New Related to DrugsWant to know what's new? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.
- FDA Drug Safety Communication: Children born to mothers who took Valproate products while pregnant may have impaired cognitive developmentOn 6/30/2011 the U.S. Food and Drug Administration (FDA) informed the public that children born to mothers who take the anti-seizure medication valproate sodium or related products (valproic acid and divalproex sodium) during pregnancy have an increased risk of lower cognitive test scores than children exposed to other anti-seizure medications during pregnancy.
- FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs[07-04-2015] The U.S. Food and Drug Administration is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS).